AVON Technologies plc — Investment Research Note

Executive summary

Avon Technologies is a UK-listed specialist in respiratory/CBRN protection (Avon Protection) and ballistic/impact helmets (Team Wendy) for military and law-enforcement end-users, with ~80% revenue from North America and the U.S. Department of War as anchor customer. Performance has inflected sharply: H1 FY26 adjusted operating margin reached 15.2% (vs. 9.4% H1 FY24 and 11.8% H1 FY25), with ROIC at 20.8%, hitting medium-term targets ~18 months early. The single most important valuation point today is that operational delivery is finally matching strategic ambition — but the share price already reflects most of that re-rating, with limited margin for disappointment from US government order phasing or the Cleveland production ramp.

Fair value estimate

Methodology: Forward earnings multiple cross-checked with EV/EBITDA, using consensus-style derivation from interim filings (H1 EPS, FY26 guidance, GBP/USD spot).

Key assumptions:

• FY26 revenue ~$330–340m (H1 $160.8m + stronger H2 per guidance, "high single-digit" growth on $326m TTM)
• FY26 adjusted operating margin towards top of 14–16% range = ~$50–53m adj operating profit
• ~$5m net finance costs, 24% effective tax rate → adjusted PAT ~$34–36m
• ~30.5m diluted shares → adjusted EPS ~$1.12–1.18 (≈ 85–90p at GBP/USD 1.32)
• Defence-specialist peer multiple range: 15–20x forward earnings
• Cross-check: EV/EBITDA ~10–13x on ~$65m forward EBITDA implies similar range

Fair value range: 1,400p – 1,800p per share (implied market cap £415m – £535m) Mid-point: ~1,600p / ~£475m

Versus current £521.7m market cap (~1,775p), the shares look full-to-slightly-rich: mid-point implies ~10% downside; the top of the range is in line with the current price. Upside vs. current price ≈ –9%; downside to bottom of range ≈ –21%. 2026-05 interim, 2025-12 AGM update, 2025-05 interim

Sector context

ICB classification (Industrial Goods & Services) is correct in form, but functionally Avon is a defence specialist with sole-source U.S. DoW contracts and a NATO framework agreement. Quality (sole-source CBRN, ROIC 20%+) is above typical Industrials peers; leverage (<1x EBITDA, $58m net debt excl. leases) is well below sector norm; growth is currently above typical industrials. Closest listed comparators: Chemring (CHG.L) for CBRN/defence specialist, QinetiQ (QQ.L) for UK defence services, and Mesa Labs (MLAB US) only as a U.S.-listed health-and-safety specialist parallel. BAE/Babcock are too large to be direct comps.

Investment thesis

• Operating leverage is now visible in margin trajectory. Cleveland ACH output up 80% vs. Sept 2025 drove Team Wendy margin from 4.4% to 5.4% with further runway as utilisation rises; Avon Protection margin already 22.3%, +340bps year-on-year on favourable mix 2026-05 interim. Group adj. operating margin progression 9.4% → 11.8% → 15.2% over three half-years demonstrates real drop-through.
• Sustained European rearmament cycle plus US DoW installed-base aftermarket. NSPA framework now serving 16 countries, $14m post-period filter order from DoW, $13m Middle East filter order, MITR adoption by Canada as first Five-Eyes nation 2026-05 interim. Avon Protection order book +19% YoY underpins multi-year visibility independent of one-off Ukraine flows.
• Quality balance sheet supports M&A optionality without forced action. Net debt 0.99x EBITDA, $137m RCF to May 2029 with $50m accordion, ROIC 20.8% 2026-05 interim. Management explicitly "not in a hurry" given elevated defence valuations — discipline rather than empire-building.

Key risks

• US government funding/shutdown volatility. Q1 FY26 was impacted by US government shutdown delaying DoW ballistic testing and DHS funding for first-responder helmets; Team Wendy orders fell 59% YoY in H1 26 partly for this reason 2026-05 interim, 2026-01 Q1 update.
• Cleveland ramp execution risk remains a named principal risk. "Cleveland ramp-up" still listed at the top of principal risks; manufacturing volatility there directly hits margin if production rates fall back 2026-05 interim §5.5. The H1 26 print already included a 7.2% Team Wendy revenue decline.
• Customer concentration on US DoW/DLA. Material exposure to single procurement agency; armor business wind-down (now complete) showed how a single test failure can destroy a segment 2021-12 final results, 2023-10 trading update. Valuation re-rating is also sensitive to NG IHPS/ACH Gen II follow-on order timing.

Operating leverage

Avon has moderate-to-high operating leverage, anchored by capacity-constrained manufacturing in Cleveland (DoW helmets) and Melksham (respiratory). Fixed cost base is significant — site overhead, R&D ($6.5m H1 26, ~4% of revenue), and central functions. Recent disclosed inflections are quantifiable: Team Wendy adj. operating profit went from $0.8m on $59.8m revenue (H1 24) to $3.2m on $73.2m (H1 25) to $3.7m on $67.9m (H1 26) — i.e. similar revenue but materially higher margin as Project Ramp matured. Avon Protection segment margin expanded from 16.5% (H1 24) → 18.9% (H1 25) → 22.3% (H1 26) on revenue growth from $67.3m → $75.5m → $92.9m. A further 10–20% revenue beat above plan would plausibly add 40–60% to operating profit at this stage of the ramp, given Cleveland is still sub-optimised (Q2 ACH output +80% vs. Sept 2025) and the Strengthen System continues to extract productivity (Group labour productivity +44% over 3 years vs. 35% target) 2026-05 interim §2.1, 2025-05 interim. The score reflects: high mix-sensitivity (Avon Protection ~22%, Team Wendy ~5% margin), genuine fixed-cost gearing in helmets, but capped by physical capacity at single-site DoW programmes.

Value-trap signals

None identified. The opposite pattern is visible: order book firm, leverage falling, margins expanding, ROIC well above cost of capital, dividend rising 6.6%. The historic value-trap signal — the body-armor business that culminated in the FY21 impairment of $46.8m and wind-down 2021-12 final results — has been fully cleared. Pension scheme deficit is being amortised and has shrunk from $40m+ to $5.7m. No related-party issues. No going-concern flags.

Earnings vs. expectations

The track record across the period is mostly meets, with one upgrade and a clean trend of margin overdelivery:

• Mar 2025 trading update: explicit upgrade to FY25 guidance (revenue growth from mid-single-digit to >10%, margin from ~11.5% to >12%) 2025-03 Q2 update
• FY25 result: medium-term margin target of 14–16% pulled forward to FY26 from FY27 2025-05 interim — H1 26 delivered into the range
• FY26 H1: "increasingly confident" of full-year guidance, expecting upper end of 14–16% margin 2026-05 interim
• Counter-example: Aug 2021 trading update was a downgrade (revenue $245–260m vs. prior expectation) due to supply chain and tariff-era ordering delays — though this is now stale and pre-current management focus.

Overall pattern under current CEO Jos Sclater (joined Jan 2023): consistent delivery, occasional positive surprises, and conservative guidance management. The H1 26 closing order book decline (-11%) is a watch-item but explained by phasing.

Conviction

4 – high.

Anchoring factors: (i) clean, KPMG-reviewed disclosure with detailed segmental data and unambiguous adjusted-vs-statutory reconciliation; (ii) three consecutive half-years of consistent margin expansion provide a robust trajectory anchor; (iii) sector multiple methodology is appropriate for a profitable, predictable defence specialist with explicit FY26 guidance.

Limiting factors: (i) terminal multiple choice meaningfully changes the answer — 15x vs. 20x is the difference between a bargain and a stretch; (ii) Cleveland production volatility could compress the H2 26 margin if Q2's gains do not stick.

Driver scoring rationale

ai_beneficiary (15): No meaningful AI-receiver exposure. Filings mention "increasing the use of AI to amplify software development, support materials science innovation, and reduce repetitive activity" 2026-05 interim §2 Transform — this is internal productivity use, not value capture in the AI value chain. Helmets and gas masks do not get a bigger TAM because the world adopts agentic AI.

operating_leverage (65): Genuine fixed-cost gearing, particularly at Cleveland; demonstrated 80% volume increase translating to margin step-up; capacity-constrained manufacturing means surprise volume earns above-average margin. Capped by capex-intensive nature and physical site limits.

earnings_surprise_trend (62): One explicit upgrade (Mar 2025), pull-forward of medium-term targets, generally meet-or-beat under current management. Not a serial beater of consensus.

cyclicality (35): Defence/security spending is currently counter-correlated with general industrial cycles; long-term programme contracts smooth revenue. Some exposure to US budget cycles and government shutdowns.

moat (70): Sole-source US DoW contracts on M50/M53A1/M69; NATO NSPA framework agreement; 4m installed mask base driving aftermarket; difficult certifications to replicate. Narrower in helmets where Team Wendy faces more competition.

leverage (22): Net debt excl. leases $58m on TTM EBITDA ~$65m = <1x. Fortress balance sheet by industrial standards.

earnings_quality (68): Adjusting items (~$5m transformation costs, $2.8m acquired-intangible amortisation per half) are real but well-disclosed; cash conversion 38% in H1 26 distorted by $18m DoW receipt timing (would have been ~100% without phasing); pension scheme deficit declining.

management_quality (75): Sclater's STAR strategy delivered medium-term targets 18 months early; clean exit from body-armor business when right call; disciplined on M&A pricing ("not in a hurry"); transparent disclosure.

growth_momentum (70): Adjusted operating profit +39.4% in H1 26, EPS +45.4%; ROIC accelerating from 16.3% to 20.8%; FY26 guidance is for "high single-digit" revenue, "top end" margin range.

Overall score rationale

This is a high-quality defence specialist trading at a fair-to-rich multiple after a strong re-rating, but it fails the investor's primary screen on AI-beneficiary exposure. The downside protection (quality balance sheet, durable contracts) and operating leverage are attractive, but valuation is no longer a margin of safety and the AI thesis is absent.